Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775200 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
A Phase 2 study, sponsored by COMPASS Pathways.
- Completed
- Registry status
- Phase 2
- Development phase
- 233
- Enrollment target
NCT03775200 is a Phase 2 study that has completed, run by COMPASS Pathways. The registered enrollment target is 233 participants.
The verdict
NCT03775200, a Phase 2 study, has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 233 participants
- Enrollment target
Study Summary
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03775200
The ClinicalTrials.gov registry entry for NCT03775200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT03775200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03775200 about?
NCT03775200 is a clinical study titled "The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression". The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
What is the current status of trial NCT03775200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2019-03-01. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT03775200?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT03775200?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.